Aurobindo Pharma Limited has informed the Exchange about receipt of approval for Dazublys biosimilar from UK s MHRA by CuraTeQ Biologics
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's wholly-owned step-down subsidiary CuraTeQ Biologics has received marketing authorization from the UK's MHRA for Dazublys, its trastuzumab biosimilar used in breast cancer treatment. This is CuraTeQ's fourth biosimilar approval from MHRA, following Bevqolva (December 2024), Zefylti (May 2025), and Dyrupeg (June 2025). Dazublys had already received EU approval in July 2025, and three of the four biosimilars are now also approved in the European Union. The approval strengthens Aurobindo's biosimilars portfolio in key regulated markets.
Positive for Aurobindo Pharma as it expands the company's biosimilar footprint in the UK and Europe, a high-value regulated market that can contribute meaningfully to future revenue from its biologics business.